Tudor Investment Corp ET AL Purchases New Position in STAAR Surgical Company $STAA

Tudor Investment Corp ET AL purchased a new position in STAAR Surgical Company (NASDAQ:STAA) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 153,052 shares of the medical instruments supplier’s stock, valued at approximately $4,113,000. Tudor Investment Corp ET AL owned approximately 0.31% of STAAR Surgical at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Polar Asset Management Partners Inc. purchased a new position in shares of STAAR Surgical during the 3rd quarter worth approximately $3,359,000. CIBC Bancorp USA Inc. purchased a new position in shares of STAAR Surgical in the 3rd quarter valued at approximately $208,000. Yunqi Capital Ltd boosted its position in shares of STAAR Surgical by 3.7% during the third quarter. Yunqi Capital Ltd now owns 2,500,061 shares of the medical instruments supplier’s stock valued at $67,177,000 after purchasing an additional 88,773 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of STAAR Surgical by 2,605.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 1,016 shares in the last quarter. Finally, Morningstar Investment Management LLC purchased a new stake in STAAR Surgical in the third quarter worth $1,070,000. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on STAA. BTIG Research reaffirmed a “neutral” rating on shares of STAAR Surgical in a research report on Tuesday, January 6th. Stifel Nicolaus lowered their price target on shares of STAAR Surgical from $19.00 to $18.00 and set a “hold” rating for the company in a research report on Wednesday, March 4th. Jefferies Financial Group dropped their price objective on shares of STAAR Surgical from $28.00 to $21.50 and set a “buy” rating on the stock in a research note on Wednesday, January 28th. Canaccord Genuity Group cut their price objective on shares of STAAR Surgical from $30.75 to $22.00 and set a “hold” rating on the stock in a report on Thursday, January 15th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research note on Tuesday, January 6th. One analyst has rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, STAAR Surgical has a consensus rating of “Reduce” and an average price target of $19.21.

STAAR Surgical Trading Up 1.2%

STAAR Surgical stock opened at $19.19 on Thursday. STAAR Surgical Company has a 12 month low of $14.69 and a 12 month high of $30.81. The company has a market capitalization of $950.10 million, a price-to-earnings ratio of -11.77 and a beta of 1.05. The business’s fifty day simple moving average is $18.53 and its two-hundred day simple moving average is $23.17.

STAAR Surgical (NASDAQ:STAA) last posted its quarterly earnings results on Tuesday, March 3rd. The medical instruments supplier reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.51). The company had revenue of $57.80 million during the quarter, compared to analysts’ expectations of $75.54 million. STAAR Surgical had a negative return on equity of 10.03% and a negative net margin of 33.60%.The firm’s revenue was up 18.0% on a year-over-year basis. On average, equities research analysts predict that STAAR Surgical Company will post -1.14 EPS for the current year.

Insiders Place Their Bets

In other news, Director Broadwood Partners, L.P. bought 316,017 shares of the firm’s stock in a transaction on Friday, March 13th. The stock was acquired at an average cost of $18.61 per share, with a total value of $5,881,076.37. Following the completion of the acquisition, the director owned 16,123,842 shares of the company’s stock, valued at approximately $300,064,699.62. This represents a 2.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have bought 1,104,351 shares of company stock worth $21,690,426. 0.59% of the stock is currently owned by company insiders.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.